SAN DIEGO, Oct. 13, 2016 /PRNewswire/ -- OncoSec
Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company
developing DNA-based intratumoral cancer immunotherapies, today
announced that new clinical data from the Phase II Investigator
Sponsored Trial led by the University of
California, San Francisco (UCSF) to assess the combination
of OncoSec's investigational intratumoral therapy,
ImmunoPulse® IL-12, and Merck's KEYTRUDA®
(pembrolizumab) in patients with unresectable metastatic melanoma
and a low likelihood of response to an anti-PD1 alone will be
presented at an oral poster presentation at the upcoming Society
for Immunotherapy of Cancer ("SITC") Annual Meeting to be held
on November 11-13, 2016, in National
Harbor, MD.
In August 2016, OncoSec announced
the publication of a research assay in the Journal of Clinical
Investigation that can be used as a predicative biomarker in
melanoma patients. The assay shows that patients with a low
frequency of CD8-positive inflamed tumors (that are PD-1 high and
CTLA-4 positive) would pre-dispose them to low response rates to
PD-1 inhibitor therapy alone. The Company is using this biomarker
assay to pre-qualify patients in this ongoing combination study
based on quantification of these type of CD8 cells. In the trial,
patients deemed to be likely low responders were treated with a
combination of systemic pembrolizumab and intratumoral
ImmunoPulse® IL-12 during the trial period. This
presentation will provide an interim update of 15 treated
patients.
The key endpoints of the study include: best overall response
rate (ORR) by RECIST v1.1 and immune-related Response Criteria
(irRC); safety and tolerability; duration of response; 24-week
landmark progression-free survival; median progression-free
survival; and overall survival.
Eligible patients were concurrently treated with pembrolizumab
and ImmunoPulse® IL-12 during the trial period.
Details of the presentation are as follows:
Abstract Title: Phase II
Study of Intratumoral plasmid Interleukin 12 (pIL-12) with
Electroporation in Combination with Pembrolizumab in Stage III/IV
Melanoma Patients with Low Tumor Infiltrating
Lymphocytes (Abstract #203921)
Lead Author: Alain Algazi,
MD, Clinical Instructor, Department of Medicine
(Hematology/Oncology), UCSF
Poster Number: 466
Date and Time: November 11, 2016 at 12:15 pm EDT (Oral poster presentation to be
defined)
Location: Prince George's Exhibition
Hall AB, Gaylord National Resort & Convention Center
For more information about this trial, please visit:
https://clinicaltrials.gov/ct2/show/NCT02493361?term=pIL-12&rank=3
About the SITC Annual Meeting
The Society for
Immunotherapy of Cancer (SITC) is a non-profit medical
professional society of influential scientists, academicians,
researchers, clinicians, government representatives, and industry
leaders from around the world dedicated to improving cancer patient
outcomes by advancing the science and application of cancer
immunotherapy. Currently, SITC has nearly 1,600 members
representing 17 medical specialties and are engaged in research and
treatment of at least a dozen types of cancer. The 31st SITC
Annual Meeting & Associated Programs will take place
November 11-13, 2016 at the
Gaylord National Hotel & Convention Center in National Harbor,
MD. For more information, please go to
http://www.sitcancer.org/2016.
About OncoSec Medical Incorporated
OncoSec is a
biotechnology company developing DNA-based intratumoral
immunotherapies with an investigational technology,
ImmunoPulse®, for the treatment of cancer.
ImmunoPulse® is designed to enhance the local delivery and uptake
of DNA-based immune-targeting agents, such as IL-12. In Phase I and
II clinical trials, ImmunoPulse® IL-12 has demonstrated
a favorable safety profile and evidence of anti-tumor activity in
the treatment of various solid tumors as well as the potential to
initiate a systemic immune response. OncoSec's lead program,
ImmunoPulse® IL-12, is currently in clinical development
for several indications, including metastatic melanoma and
triple-negative breast cancer. The program's current focus is on
the significant unmet medical need in patients with melanoma who
are refractory or non-responsive to anti-PD-1/PD-L1 therapies. In
addition to ImmunoPulse® IL-12, the Company is also
identifying and developing new immune-targeting agents for use with
the ImmunoPulse® platform. For more information, please
visit www.oncosec.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains "forward-looking
statements" within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995. Forward-looking statements can be
identified by words such as "will," "can," and similar references
to future periods.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based on
management's current preliminary expectations and are subject to
risks and uncertainties, which may cause our results to differ
materially and adversely from the statements contained herein.
Potential risks and uncertainties that could cause actual results
to differ from those predicted include, among others, the
following: uncertainties inherent in pre-clinical studies and
clinical trials, such as the ability to enroll patients in clinical
trials and the risk of adverse events; unexpected new data,
safety and technical issues; our ability to raise additional
funding necessary to fund continued operations; and the other
factors discussed in OncoSec's filings with the Securities and
Exchange Commission.
Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
disclaims any obligation to update any forward-looking statements
to reflect new information, events or circumstances after the date
they are made, or to reflect the occurrence of unanticipated
events.
Contact
Sophia Ononye, PhD MPH MBA
Associate Director, Investor Relations and Corporate
Communications
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com
Logo -
http://photos.prnewswire.com/prnh/20120905/LA68078LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/oncosec-announces-acceptance-of-late-breaking-abstract-at-upcoming-society-for-immunotherapy-of-cancer-sitc-annual-meeting-2016-300344083.html
SOURCE OncoSec Medical Incorporated